EXAS 59.4 (+5.86%)
US30063P1057Medical Diagnostics & ResearchDiagnostics & Research

Exact Sciences (EXAS) Stock Highlights

59.4 | +5.86%
2024-12-21 01:20:21
Exact Sciences Corporation, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exacts Cologuard screening test, a non-invasive stool-based DNA test, is a pre-cancer screening test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a genetic-based treatment selection test for breast, prostate, and colon cancers. With the acquisitions of Base Genomics and Thrive Earlier Detection, Exact is building a multi-cancer early screening test to detect over 14 cancers, a test that would be one of the earliest entrants in multi-cancer liquid biopsy cancer screening.

Statistics

Range Today
55.98 59.7
Volume Today 2.73M
Range 1 Year
40.62 79.62
Volume 1 Year 652.98M
Range 3 Year
29.27 100.77
Volume 3 Year 1.67B
Range 10 Year
4.67 159.54
Volume 10 Year 5.56B

Highlights

Market Capitalization 9.53B (mid)
Floating Shares 183.74M
Current Price 59.4
Price To Earnings -45.82
Price To Revenue 4.31
Price To Book 2.97
Earnings Per Share -1.16
Payout Ratio 0%

Performance

Latest +5.86%
1 Month +9.72%
3 Months -15.61%
6 Months +42.07%
1 Year -19.51%
3 Years -25.07%
5 Years -38.67%
10 Years +116%

Benchmarks


Obligatory risk notice

We would like to point out that the contents of this website are for general information purposes only and do not constitute recommendations for the purchase or sale of specific financial instruments, and therefore do not constitute investment advice. In particular, marketstorylabs.com and its creators cannot assess the extent to which information / recommendations made on the pages correspond to your investment objectives, your risk tolerance and your ability to bear losses. Therefore, if you make any investment decisions based on information on the site, you do so solely on your own responsibility and at your own risk. This in turn means that neither marketstorylabs.com nor its creators are liable for any losses incurred as a result of investment decisions based on the information on the marketstorylabs.com website or other media used.